About Annexon
Annexon is a company based in San Francisco (United States) founded in 2011. Annexon has raised $256 million across 6 funding rounds from investors including Blackstone, BlackRock and Bain Capital. The company has 100 employees as of December 31, 2024. Annexon offers products and services including ANX005, ANX007, and ANX1502. Annexon operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Syndax and Horizon Therapeutics, among others.
- Headquarter San Francisco, United States
- Employees 100 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Annexon, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$138.2 M (USD)-2.95as on Dec 31, 2024
-
EBITDA
-$150.62 M (USD)-7.24as on Dec 31, 2024
-
Total Equity Funding
$256 M (USD)
in 6 rounds
-
Latest Funding Round
$130.48 M (USD), Post-IPO
Jul 08, 2022
-
Investors
Blackstone
& 17 more
-
Employee Count
100
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Annexon
Annexon is a publicly listed company on the NASDAQ with ticker symbol ANNX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Annexon
Annexon offers a comprehensive portfolio of products and services, including ANX005, ANX007, and ANX1502.
Antibody for treating Guillain-Barré syndrome by inhibiting C1q.
Inhibitor for eye diseases via intravitreal administration.
Targets C1q for autoimmune diseases in clinical trials.
People of Annexon
Unlock access to complete
Unlock access to complete
Leadership Team
33 people
Operations Team
8 people
Scientific Team
6 people
Board Team
5 people
Software Development Team
4 people
Product Management Team
4 people
Finance and Accounting
3 people
Human Resources and Administration
2 people
Unlock access to complete
Funding Insights of Annexon
Annexon has successfully raised a total of $256M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $130.48 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Annexon
Annexon has secured backing from 18 investors, including institutional and venture fund investors. Prominent investors backing the company include Blackstone, BlackRock and Bain Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are focused on pharmaceutical, biotechnology, and medical sectors.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on tech sectors
|
Locked | Locked | Locked | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked |
Investor details for Annexon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Annexon
Investment portfolio details for Annexon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Annexon
Detailed financials for Annexon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Annexon Comparisons
Peer comparison for Annexon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Annexon
Annexon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Syndax and Horizon Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Targeted therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
Detailed competitors of Annexon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Annexon
Complete news archive for Annexon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Annexon
Annexon was founded in 2011.
Annexon is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Annexon is a funded company, having raised a total of $256M across 6 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Annexon is 100.
Developer of antibodies to treat complement-mediated neurodegenerative diseases. The company is developing the antibody pipeline is based on research involving the classical complement pathway and the role of its initiating molecule, C1q, in the loss of nerve connections and inflammation. It claims to focus on treating diseases such as Alzheimers disease, Huntingtons disease, and other neurodegenerative disorders.
Annexon offers ANX005, ANX007, and ANX1502.
Yes, Annexon is publicly traded on NASDAQ under the ticker symbol ANNX.
Annexon has 18 investors. Key investors include Blackstone, BlackRock, Bain Capital, Citadel, and Janus Henderson Investors.
The ticker symbol of Annexon is ANNX on NASDAQ.